Company Profile

23andMe Inc
Profile last edited on: 10/31/22      CAGE: 4TGW5      UEI: JUVFHKN9XCY3

Business Identifier: Human genome research: enabling clients to study their ancestry, genealogy, and inherited traits: home DNA test kits
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1390 Shorebird Way
Mountain View, CA 94043
   (650) 938-6300
Location: Single
Congr. District: 18
County: Santa Clara

Public Profile

Active in the SBIR arena for about a decade - last NIH dollars in 2016, 23andMe, Inc. (NASDAQ:ME) operates as a personal genetics company enabling users to study their ancestry, genealogy, and inherited traits. Operating as a privately held firm until Jun 17, 2021 when the firm went public through a merger with a Richard Branson SPAC, VG Acquisition Corp., in a deal that raised near-$600 million and valued the company at $3.5B. The firm offers Users the option to search and explore genes contributing to their personal characteristics eg lactose intolerance, athletic ability, and food preferences; learn how the research studies relate to their genomes; compare their profiles to family and friends; and to discover their genetic roots, as well as to gain insights into their ancestry, genealogy, and inherited traits. The firm's tools also enables users to understand their own genetic information using DNA analysis technologies and Web-based interactive tools. The vision for 23andMe is described as personalizing healthcare by making and supporting meaningful discoveries through genetic research.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Linda Avey -- Co-Founder & Chief Executive Officer

  Anne Wojcicki -- Co Founder, Chief Executive Officer and Director

  Adam Auton -- Senior Statistical Geneticist

  Katarzyna Bryc -- Senior Scientist, Population Genetics

  Angela Calman -- Vice President, Communications

  Emily Drabant Conley -- Vice President, Business Development

  Nicholas A Furlotte

  Ruby Gadelrab -- Vice President, Commercial Marketing

  Robert Gentleman -- Vice President, Computational Biology

  Jill Hagenkord -- Chief Medical Officer

  Kathy Hibbs -- Chief Legal and Regulatory Officer

  David Alan Hinds -- Principal Scientist, Statistical Genetics

  Tracy Keim -- Vice President, Consumer Marketing & Brand

  Steve Lemon -- Vice President, Engineering

  Joanna L Mountain -- Senior Director of Research

  Andrew Page -- Board Member

  Neil Rothstein -- VP Mktg.

  Richard Scheller -- Chief Science Officer & Head of Therapeutics

  Dean Schorno -- Chief Financial Officer & Head of Operations

  Steve Schwartz -- VP, Business Development & Strategy

  Joyce Tung -- Vice President, Research

  Jonnathan Ward -- Vice President, Consumer Marketing | Acquisition